drugset / Trial / NCT07122102

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes

NCT07122102

Not yet recruiting 200 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will compare the effect and safety of cofrogliptin (HSK7653) with acarbose among people with type 2 diabetes

Timeline

Start
2025-10-01
Primary completion
2027-06-30
Completion
2027-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acarbose Unknown 50 mg
Subject Cofrogliptin Small molecule 10 mg